TICKERNERD
Menu
KARDHealthcare · Biotechnology

KARD Stock Forecast: Kardigan, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$19
−0.91% on the day

The 4 Wall Street analysts covering Kardigan, Inc. hold a median 12-month price target of $43 — +132.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 0 of 100 as at 12 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.7B
Ticker Nerd rank
0 / 100
Median analyst target
$43
Analysts covering
4
Revenue$0.0
Operating income−$75.2M
Net income−$116.2M
Free cash flow−$52.8M
Quarterly, 4 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−10.7%
1M
−16.0%
From high
−28.5%
From low
0.0%
$19
$26
Range since 18 June 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

KARD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Kardigan, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
0 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
38
Revisions
27
Issuance
9
Value
8
Growth
8
Accruals
8
Quality
4
Volatility
3
Momentum
2

Size (38): Smaller than most of the companies we track.

Momentum (2): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

KARD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KARD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 18 June 2026Adjusted close, US dollars
$15$20$25$30$35$40$45$50Jul 26Aug 26Sep 26KARDHigh $46Median $43Low $37

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $37Median $43High $46

The green dot is the last close — the median target sits +132.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
25 Aug 2026JP MorganMaintainsOverweight$51 → $46
13 July 2026JefferiesInitiatesBuy$40
13 July 2026JefferiesInitiatesBuy—
13 July 2026JP MorganInitiatesOverweight—
13 July 2026JP MorganInitiatesOverweight$51
13 July 2026Leerink PartnersInitiatesOutperform$37
13 July 2026Leerink PartnersInitiatesOutperform—
13 July 2026TD CowenInitiatesBuy—
13 July 2026TD CowenInitiatesBuy$46

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KARD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

KARD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

KARD vs S&P 500, last 12 monthsTotal return, rebased to 100
859095100105110Jul 26Aug 26Sep 26KARDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KARD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Kardigan, Inc. (KARD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.8×

Cheaper than 90% of US stocks

Price / sales
—
Price / book
2.8×

Cheaper than 35% of US stocks

EV / EBITDA
−4.3×

Cheaper than 78% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
76.7%

Higher than 95% of US stocks

Return on assets
−49.1%

Higher than 8% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Kardigan, Inc. (KARD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Kardigan, Inc. has a market value of $1.7B and an enterprise value of $1.1B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$247.8M.

  • Diluted earnings per share, trailing twelve months: $−6.72.

  • Free cash flow in the twelve months to 30 June 2026: −$167.6M, after $2.8M of capital spending.

  • Shares outstanding: 89.3M.

  • Trailing P/E: −5.8×; forward P/E: −5.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Kardigan, Inc. employs 241 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

KARD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KARDKardigan, Inc.$1.7B
0
KLRAKailera Therapeutics, Inc.$1.7B
1
SEPNSepterna, Inc.$1.7B
90
XNCRXencor, Inc.$1.7B
79
DMRADamora Therapeutics, Inc.$1.7B
45
MRVIMaravai Lifesciences Holdings, Inc.$1.7B
87
RXRXRecursion Pharmaceuticals, Inc.$1.7B
44

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Kardigan, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KARD news & analysis

Kardigan: Funded Precision Cardiology Offers More Than Pipeline Diversification

Seeking Alpha · 13 Sept 2026neutral

Seeking Alpha reports that Kardigan is running biology-driven clinical programs targeting genetic DCM, moderate CAVS, and post-hospitalization ASH. The company holds $660.7M in liquid assets, providing roughly 2-3 years of runway to reach key clinical readouts, with data from all three lead programs expected in 2027.

Why it matters — KARD watchers would care because 2027 data from all three lead programs will be pivotal in validating the company's hypotheses and informing future capital allocation.

Kardigan to Present at Two September Investor Conferences

Business Wire · 2 Sept 2026neutral

Kardigan (KARD) will participate in two upcoming investor conferences: the 2026 Cantor Global Healthcare Conference and Baird's 2026 Global Healthcare Conference.

Why it matters — Presenting at these conferences gives Kardigan the opportunity to showcase its business and strategy to a broader investor audience.

Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates

Business Wire · 11 Aug 2026neutral

Kardigan, Inc. (Nasdaq: KARD) reported its second quarter 2026 financial results for the period ended June 30, 2026, and provided recent business updates. The announcement was made via Business Wire from the company's South San Francisco and Princeton locations.

Why it matters — This is Kardigan's official quarterly financial report, which KARD watchers would use to assess the company's most recent operating performance.

FAQ

Frequently asked questions about KARD stock

What is the KARD stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Kardigan, Inc. have a median 12-month price target of $43, with estimates ranging from $37 to $46. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KARD stock a buy right now?

Of the 4 analysts covering Kardigan, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kardigan, Inc. 0 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KARD?

As at 12 Sept 2026, Kardigan, Inc. ranks 0 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (38 of 100).

Will KARD stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +132.2% from the last close, and Ticker Nerd's factor model ranks Kardigan, Inc. 0 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KARD stock forecast for 2030?

No analyst covering Kardigan, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KARD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $37 to $46 over the next 12 months.

What does Kardigan, Inc. do?

Kardigan Inc. is a biopharmaceutical company focused on developing medicines for cardiovascular diseases.

What is the latest news on KARD?

The most recent item we track (Seeking Alpha, 13 Sept 2026): "Kardigan: Funded Precision Cardiology Offers More Than Pipeline Diversification". Seeking Alpha reports that Kardigan is running biology-driven clinical programs targeting genetic DCM, moderate CAVS, and post-hospitalization ASH. The company holds $660.7M in liquid assets, providing roughly 2-3 years of runway to reach key clinical readouts, with data from all three lead programs expected in 2027.

Company

About Kardigan, Inc.

Kardigan Inc. is a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company works on targeted therapies designed to address the underlying disease mechanisms behind specific heart conditions, including cardiomyopathies that can lead to heart failure. Its current pipeline centers on clinical-stage cardiovascular programs aimed at diseases where approved treatment options remain limited or unavailable. Kardigan also uses a research and translational platform that combines clinical data, analytics, and precision medicine approaches to support drug discovery and development. The company operates as a single segment business centered on cardiovascular therapeutics and serves the broader healthcare and biotechnology market. Kardigan Inc. is headquartered in Princeton, New Jersey, and maintains its operational base in South San Francisco, California.

CEO Mr. Tassos Anastasios E. Gianakakos M.Sc., MBA · 241 employees · United States · https://www.kardigan.bio